Skip to main content

Beyond Air, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

XAIR$2.52+10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)

For the Six Months Ended
September 30,
2025 · 2024
Cash flows from operating activities
Net loss$(16,336)$(27,083)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation1,5231,468
Amortization of licensed right to use technology102102
Stock-based compensation3,3526,508
Amortization of debt discount and accretion of debt issuance costs133778
Change in fair value of warrant liability(16)(214)
Change in fair value of derivative liability-(1,314)
Amortization of operating lease assets217206
Paid in kind interest837-
Provision for inventory losses239333
Foreign currency adjustments(138)-
Loss on extinguishment of debt-624
Loss on termination of right of use asset-49
Loss on disposal of fixed assets57171
Unrealized gain in marketable securities(4)(9)
Changes in:
Inventory492(732)
Accounts receivable(182)(237)
Other current assets and prepaid expenses941516
Accounts payable(35)(517)
Accrued expenses9(3,932)
Operating lease liabilities(170)(246)
Net cash used in operating activities$(8,979)$(23,528)
Cash flows from investing activities
Purchase of marketable securities(3)(18,481)
Proceeds from sale of marketable securities1,26341,581
Issue of/return of security deposits-10
Purchase of property and equipment(444)(3,848)
Net cash provided by investing activities$816$19,261
Cash flows from financing activities
Proceeds from issuance of common stock through at the market offerings8,135642
Proceeds from the sale of common stock of NeuroNos500-
Proceeds from issuance of common stock through exercise of warrants2,868-
Issuance of common stock warrants9086
Issuance of common stock and pre-funded warrants through securities purchase agreement II-18,858
Proceeds from long-term loan2,0007,500
Payment of loans(609)(5,726)
Net cash provided by financing activities$12,984$21,360
Effect of exchange rate changes on cash and cash equivalents145(23)
Increase in cash, cash equivalents and restricted cash$4,966$17,069
Cash, cash equivalents and restricted cash at beginning of period4,89611,608
Cash, cash equivalents and restricted cash at end of period$9,862$28,677
Supplemental disclosure of non-cash investing and financing activities
Debt discount$-$853
End of term loan liability$-$(138)
Warrant liability$-$(214)
Derivative liability$-$(1,314)
Right-of-use assets$-$(309)
Operating lease liability$-$(309)
Cash receivable as part of Securities Purchase Agreement II$-$370
Supplemental disclosure of cash flow items:
Interest paid$195$1,110
Income taxes paid$-$-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.